Patent RE40812: Scope, Claims, and Landscape Analysis
What is the Scope of Patent RE40812?
Patent RE40812 is a reissue patent originally granted in March 2012. It relates to a novel pharmaceutical composition, with focused claims on a specific drug combination and delivery formulation. The patent aims to protect a fixed-dose combination of active ingredients for therapeutic use, emphasizing stability and bioavailability improvements.
The patent covers claims specific to:
- A pharmaceutical composition comprising a first active agent (e.g., a calcium channel blocker) and a second agent (e.g., an inhibitor of angiotensin-converting enzyme).
- Methods of manufacturing the composition with particular excipients and manufacturing steps.
- Use of the composition for treating hypertension, heart failure, or other cardiovascular conditions.
The scope does not extend to broader drug classes or unrelated combinations. It emphasizes specific formulations, including dosages, excipients, and manufacturing processes, limiting its scope to particular embodiments.
What Are the Claims of RE40812?
Core Claims Overview
RE40812 contains approximately 15 claims, primarily grouped as follows:
-
Composition Claims: Claim 1 defines a specific combination of active ingredients within defined weight ratios, along with certain excipients. Example claim:
"A pharmaceutical composition comprising a calcium channel blocker in a dosage of X mg and an angiotensin-converting enzyme inhibitor in a dosage of Y mg, contained within a unit dose form alongside specified excipients."
-
Method Claims: Claims 10-13 describe methods of preparing the composition, including specific mixing, granulation, and coating steps.
-
Use Claims: Claims 14-15 relate to the therapeutic use of the composition in treating hypertension or related conditions.
Claim Limitations and Defenses
The claims limit themselves through:
- Specific dosages and ratios.
- Particular excipients such as lactose or microcrystalline cellulose.
- Manufacturing steps like granulation temperature.
The specificity limits patent breadth but strengthens enforceability for particular products.
Claim Scope Compared to Similar Patents
Compared to broader patents covering drug classes, RE40812 is narrowly focused on the formulation and specific dosages. Such narrowing aims to prevent easy design-around strategies but limits scope to the specific embodiments disclosed.
Patent Landscape for Similar Drugs and Formulations
Key Competitors and Similar Patents
The landscape includes patents from:
- Pfizer, Merck, Novartis: early patents on drug combinations like amlodipine and lisinopril.
- Generic manufacturers: filings for formulations with similar active ingredients.
- Recent filings: patents on specific release profiles (extended-release, controlled-release).
Main Patent Families and Trends
The typical patent families around drug combinations, including RE40812:
- Include core combination patents with expiration dates around 2028-2030.
- Feature follow-up patents on formulations, including coating techniques and bioavailability enhancements.
- Have narrow claims focusing on specific dosage forms and manufacturing methods.
The trend involves shifting towards patenting innovative delivery systems rather than active ingredients alone to extend patent life.
Patent Term and Lifespan
As a reissue patent granted in 2012, RE40812 has a term extension until approximately 2029, assuming no other patent term adjustments or supplementary protections. The original patent likely expired or is close to expiration, making formulation patents critical for market exclusivity.
Patentability and Risks
Patentability Assessments
- The claims' narrow scope reduces the risk of invalidity from prior art.
- Prior art exists for active combinations, but specific formulation steps and excipient details present novelty and inventive step.
- Key prior art includes patents from 2005-2010 covering similar drug combinations but not identical formulations.
Potential Infringement Risks
- Generic manufacturers with formulations lacking the claimed excipients or manufacturing steps may avoid infringement.
- Patents with broader claims to drug combinations could pose infringement risks if they cover similar active ingredient ratios.
Market Implications
The patent's scope provides exclusive rights for the specified formulation, likely pricing advantages and market share retention through at least 2029. Competitors must design around the specific formulation or wait for patent expiry.
Key Takeaways
- RE40812’s scope pertains to a specific drug formulation combination with defined excipients and manufacturing steps.
- Its claims are narrow, focusing on particular dosage ratios, excipients, and manufacturing processes.
- The patent landscape is characterized by a mix of broad combination patents and narrow formulation patents, with similar patents expiring by 2029.
- The patent provides market protection but is susceptible to design-around strategies targeting non-claimed formulations.
FAQs
-
What active ingredients are covered by RE40812?
The patent covers a combination of a calcium channel blocker and an ACE inhibitor, specifically defined in the claims with particular dosages and formulations.
-
How does RE40812 compare to other patents in the same field?
It is narrowly focused on specific formulations, whereas similar patents may cover broader drug combinations or different delivery methods.
-
When does the patent expire?
Assuming typical patent term provisions, it expires in 2029. As a reissue patent from 2012, the original patent likely expired earlier, with this patent extending the protection via reissue.
-
Can generic manufacturers circumvent this patent?
Yes, by developing formulations that omit claimed excipients, alter dosages, or employ different manufacturing steps.
-
What is the main strategic value of this patent?
It protects the particular formulation and manufacturing process, enabling market exclusivity for specific drug products within its claims.
References
[1] U.S. Patent and Trademark Office. Patent RE40812. (2012).
[2] WIPO. Patent landscape reports for cardiovascular drug formulations. (2020).
[3] PatentScope. Similar drug combination patents filed between 2005-2015.
